 |
SK바이오사이언스 (사진 = SK바이오사이언스 홈페이지) |
[Alpha Biz= Paul Lee] Shares of SK Bioscience surged during morning trading on May 21 following news that the company won a final Supreme Court ruling in a patent infringement lawsuit filed by Pfizer.
As of 9:50 a.m. KST, SK Bioscience stock was trading at ₩43,100, up ₩2,500 (6.15%) from the previous day. Earlier in the session, shares had jumped nearly 10% to ₩45,100.
SK Bioscience announced that South Korea’s Supreme Court had upheld a lower court’s ruling in favor of the company, dismissing Pfizer’s claims regarding patent infringement on its 13-valent pneumococcal conjugate vaccine (PCV13), known commercially as Prevnar 13.
Pfizer had initially filed the lawsuit in 2020, alleging that SK Bioscience’s supply of PCV13 monovalent bulk substances and research-use finished products to Russia infringed on the composition patent of Prevnar 13.
However, the Supreme Court affirmed that the individual monovalent conjugates comprising PCV13 did not fall within the scope of Pfizer’s patent claims. It also ruled that SK Bioscience’s manufacture and supply of the PCV13 product for research and trial purposes did not constitute patent infringement.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
